Table 5

Details of individual ambulatory care expenditures for patients with T2DM and normal renal function and for non-diabetic controls in 2010 (€)
Consultations visits Physio-therapist Nursing care Biological diagnostic tests Radiology/medical imaging Medical devices Transportation Invalidity Pharmacy Others Total ambulatory care costs
Monotherapy (mono): m (σ) 256 (190) 90 (339) 144 (853) 159 (175) 113 (191) 272 (861) 88 (449) 219 (1,451) 1,156 (1,786) 521 (1,528) 3,017 (3,829)
Double therapy (bi): m (σ) 257 (156) 88 (372) 152(885) 155 (158) 107 (186) 294 (728) 98 (787) 240 (1,730) 1,411 (1,650) 506 (1,679) 3,308 (4,045)
Cost ratio vs mono 1.045 0.909 1.392 1.070 0.940 1.237 1.113 0.976 1.236 0.885 1.102
Triple therapy (tri): m (σ) 252 (146) 55(280) 94 (646) 149 (129) 110 (188) 272 (410) 112 (707) 308 (1,857) 1,798 (1,509) 460 (1,337) 3,609(3,801)
Cost ratio vs bi 1.044 0.728 0.675 0.977 1.038 1.059 1.022 1.026 1.287 0.926 1.101
Insulin therapy: m (σ) 329 (208) 157 (499) 1,586 (2761) 198 (210) 140 (221) 1,216 (1,697) 264 (1,064) 444 (2,025) 2,646 (2,124) 420 (1,093) 7,398(5,487)
Cost ratio vs tri 1.200 2.509 18.420 1.189 1.178 3.931 2.480 2.929 1.331 1.228 1.942
Non diabetic patients 175 (184) 81 (324) 101 (977) 93 (176) 95 (170) 160 (805) 85 (582) 136 (1,131) 702 (2,142) 538 (1,799) 2,166 (4,102)
Additional costs vs non diabetic patients: € (increase rate in %)
Monotherapy 80 (46.3%) 9 (11.1%) 43 (42.6%) 66 (71.0%) 18 (18.9%) 112 (70.0%) 3 (3.5%) 83 (61.0%) 454 (64.7%) −17 (-3.2%) 852 (39.3%)
Double therapy 81 (46.9%) 7 (8.6%) 51 (50.5%) 62 (66.7%) 12 (12.6%) 134 (83.8%) 13 (15.3%) 104 (76.5%) 709 (101.0%) −32 (-5.9%) 1,142 (52.7%)
Triple therapy 77 (44.0%) −26 (-32.1%) −7 (-6.9%) 56 (60.2%) 15 (15.8%) 112 (70.0%) 27 (31.8%) 172 (126.5%) 1,096 (156.1%) −78 (-14.5%) 1,444 (66.7%)
Insulin therapy 154 (88.0%) 76 (93.8%) 1,485 (1,470.3%) 105 (112.9%) 45 (47.4%) 1,056 (660.0%) 179 (210.6%) 308 (226.5%) 1,944 (276.9%) −118 (-21.9%) 5,234 (241.7%)

*Cost ratios from Generalized Linear Models (GLM), adjusted on year, socio demographic patient characteristics, long-term conditions, co-treatments.

Guelfucci et al.

Guelfucci et al. BMC Endocrine Disorders 2013 13:15   doi:10.1186/1472-6823-13-15

Open Data